Related posts:

1. Washington DC Share of Cost, Kyrgyzstan: Tension And Violence Continue In The South Washington DC Share of Cost, Kyrgyzstan: Tension And Violence Continue In The South: Five weeks after violent clashes erupted in the south of Kyrgyzstan, and despite an apparent return to a more peaceful situation, doctors, psychologists, and nurses working with the international humanitarian medical organization, Doctors Without Borders/MÃdecins Sans Fronti¨res (MSF) continue to deal with […]...
2. Share of Cost, Brand Castle, LLC Issues Allergy Alert On Undeclared Egg In Icing Of Licensed Rice Krispies Treats Holiday Village Kit Share of Cost, Brand Castle, LLC Issues Allergy Alert On Undeclared Egg In Icing Of Licensed Rice Krispies Treats Holiday Village Kit...
3. Madison Nation Life Insurance Company Offers Dental Insurance With ShareOfCost.com Madison Nation Life Insurance Company Offers Dental Insurance With ShareOfCost.com...
4. When is the best time to buy a Medigap policy? When is the best time to buy a Medigap policy?...
5. How do insurance companies set prices for Medigap policies? How do insurance companies set prices for Medigap policies?...
6. Statement By The World Food Programme Executive Director Josette Sheeran On The Conflict In Sudan It is the height of the hunger season in Sudan and the violence that has engulfed South Kordofan is hindering WFP’s efforts to reach hundreds of thousands of people in need of food assistance. As the security situation in South Kordofan state deteriorates, I would like to echo the UN Secretary General’s deep concern about […]...
7. U.S. Department of Justice (DOJ) Announces Settlement with AMC Entertainment Inc. DOJ has reached an agreement with AMC Entertainment Inc. to settle a lawsuit filed in 1999 under the Americans with Disabilities Act (ADA). The suit claimed that the design of stadium-style movie theaters did not provide persons who use wheelchairs with the same lines of sight as other moviegoers. All AMC stadium-style theaters that are opened after the […]...
8. Phadia First Company To Receive FDA Clearance Of Recombinant Allergen Component Tests Phadia, the global leader in allergy and autoimmunity diagnostics, today announced the FDA clearance of recombinant ImmunoCAP® Allergen Components for marketing in the United States. The FDA clearance applies to all of Phadia’s instrument platforms....
9. HUD Announces New Program to Help Homeowners at Risk of Foreclosure Share of Cost: The U.S. Department of Housing and Urban Development (HUD) and NeighborWorks® America have announced a new program called the Emergency Homeowners’ Loan Program (EHLP). EHLP helps homeowners who have experienced a reduction in income and are at risk of foreclosure due to involuntary unemployment, underemployment due to economic conditions or a medical condition. […]...
10. Employers Still Excluding Large Groups of People from Jobs Based on Race, Sex, Age & Disability Experts testified at a U.S. Equal Employment Opportunity Commission (EEOC) meeting that employers nationwide continue to discriminate against job seekers based on their race, sex, age, national origin, disability or other prohibited bases. An EEOC trial attorney described the case of two deaf applicants who were denied employment by Walmart because they were deaf. The public can submit written comments by mail […]...
11. Medtronic Announces $750,000 In Funding To Support Healthcare Infrastructure Development In Haiti Medtronic, Inc. (NYSE: MDT) announced today $750,000 in grants through the Medtronic Foundation to support continued healthcare infrastructure development in Haiti. Partners in Health will receive $500,000 to help complete construction of a public hospital in the Central Plateau city of Mirebalais....
12. Teva Respiratory Announces Positive Results From Phase III Trial Of BDP HFA Nasal Aerosol In Seasonal Allergic Rhinitis Teva Respiratory announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to a placebo....